Abstract

Background

Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease.

Methods

A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria.

Results

The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively (p value = .869). The mean MELD (i), MELD-Na, MELD New, UKELD, and Child-Pugh scores were 14.36 ± 4.26, 15.26 ± 4.81, 14.74 ± 4.66, 52.33 ± 3.82, and 7.28 ± 1.50, respectively. In this study, circulating levels of GLP-1 were statistically lower in cirrhotic patients compared with healthy controls (95.26 ± 17.15 vs 111.84 ± 38.14 pg/mL; p value = .017).

Conclusion

Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals.

中文翻译：

---

肝硬化患者循环胰高血糖素样肽-1水平

摘要

背景

胰高血糖素样肽-1 (GLP-1) 是一种肠道来源的肠促胰岛素激素，在葡萄糖诱导的胰岛素分泌中起着关键作用。目前，肠降血糖素在肝硬化发病机制中的作用尚不明确。本研究旨在调查肝硬化患者 GLP-1 的循环水平及其与肝病严重程度的关系。

方法

这项横断面研究共招募了 80 名参与者，包括 39 名确诊为肝硬化的患者和 41 名健康对照者。使用 ELISA 方法测定 GLP-1 的循环水平。根据 Child-Pugh、MELD (i)、MELD-Na、MELD New 和英国终末期肝病评分 (UKELD) 标准评估肝硬化的严重程度。

结果

患者和健康受试者的平均年龄分别为 42.51 ± 12.80 和 42.07 ± 10.92 岁（p值 = .869）。平均 MELD (i)、MELD-Na、MELD New、UKELD 和 Child-Pugh 评分分别为 14.36 ± 4.26、15.26 ± 4.81、14.74 ± 4.66、52.33 ± 3.82 和 7.28 ± 1.50。在这项研究中，与健康对照组相比，肝硬化患者的 GLP-1 循环水平在统计学上较低（95.26 ± 17.15 vs 111.84 ± 38.14 pg/mL；p值 = .017）。

结论

与健康个体相比，需要更大规模的前瞻性研究来探索肠促胰岛素对肝硬化患者的影响。